Dysregulation of glutamine/glutamate metabolism in COVID-19 patients: A metabolism study in African population and mini meta-analysis

Xiao-kun Li1 | Bo Tu2 | Xiao-Ai Zhang1 | Wen Xu2 | Jia-hao Chen1 | Guang-Yu Zhao1 | Biao Xu2 | Jun-Jie Zheng2 | Yan-Feng Yan1 | Peng-Fei Hao3 | Reginald Cole4 | Mohamed Boie Jalloh4 | Qing-Bin Lu5 | Chang Li3 | Stephen Sevalie4 | Wei Liu1 | Wei-Wei Chen2

1State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China
2Fifth Medical Center of Chinese PLA General Hospital, Beijing, China
3Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, China
4Joint Medical Unit, Republic of Sierra Leone Armed Forces, Freetown, Sierra Leone
5Department of Laboratory Science and Technology School of Public Health, Peking University, Beijing, China

Correspondence
Wei-wei Chen, Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China.
Email: cww302@126.com

Stephen Sevalie, Joint Medical Unit, Republic of Sierra Leone Armed Forces, 34 Military Hospital Wilberforce Freetown, Freetown, Sierra Leone.
Email: stevesylo@gmail.com

Wei Liu, State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.
Email: liuwei@bmi.ac.cn

Funding Information
National Key R&D Program of China; Biomedical research foundation, Grant/Award Number: 195WAQ13; National Natural Science Foundation of China

Abstract
Coronavirus disease 2019 (COVID-19) remains a serious global threat. The metabolic analysis had been successfully applied in the efforts to uncover the pathological mechanisms and biomarkers of disease severity. Here we performed a quasi-targeted metabolomic analysis on 56 COVID-19 patients from Sierra Leone in western Africa, revealing the metabolomic profiles and the association with disease severity, which was confirmed by the targeted metabolomic analysis of 19 pairs of COVID-19 patients. A meta-analysis was performed on published metabolic data of COVID-19 to verify our findings. Of the 596 identified metabolites, 58 showed significant differences between severe and nonsevere groups. The pathway enrichment of these differential metabolites revealed glutamine and glutamate metabolism as the most significant metabolic pathway (Impact = 0.5; −log10P = 1.959). Further targeted metabolic analysis revealed six metabolites with significant intergroup differences, with glutamine/glutamate ratio significantly associated with severe disease, negatively correlated with 10 clinical parameters and positively correlated with SPO2 (rs = 0.442, p = 0.005). Mini meta-analysis indicated elevated glutamate was related to increased risk of COVID-19 infection (pooled odd ratio [OR] = 2.02; 95% confidence interval [CI]: 1.17–3.50) and severe COVID-19 (pooled OR = 2.28; 95% CI: 1.14–4.56). In contrast, elevated glutamine related to decreased risk of infection and severe COVID-19, the pooled OR were 0.30 (95% CI: 0.20–0.44), and 0.44 (95% CI: 0.19–0.98), respectively. Glutamine and glutamate metabolism are associated with COVID-19 severity in multiple populations, which might confer potential therapeutic target of COVID-19, especially for severe patients.

KEYWORDS
biomarkers, COVID-19, glutamate, glutamine, meta-analysis, metabolism
1 | INTRODUCTION

Despite advances in public health interventions, antiviral drugs development and multiple vaccination strategies, coronavirus disease 2019 (COVID-19) remains a serious global threat. By the end of March 2022, over 469,212,705 confirmed cases with 6,077,252 deaths (overall mortality rate 1.29%) worldwide were reported to World Health Organization (WHO) (https://covid19.who.int/). COVID-19 ranged widely from asymptomatic and unspecific symptoms to severe respiratory distress and multiorgan failure or even death.1,2 The severity rate of COVID-19 patients in China, 14% (6188 cases) were severe and 5% (2087) were critical.4 The mortality rate in patients who required mechanical ventilation (severe) reaches up to 88.1%, which is much higher compared with patients who did not receive mechanical ventilation (nonsevere and mortality rate 11.7%).3

The early diagnosis and prognosis of COVID-19 are important for proper healthcare resource allocation and treatment of severe patients, this was greatly hindered by the lack of an appropriate prognostic indicators for early recognition of adverse outcome. Metabolomic phenotyping, the simultaneous measurement of multiple small molecules in a biological sample, can provide a comprehensive assessment of an individual’s biochemical status. Application and integration of metabolomic technologies was one of the most intensively explored approach to demonstrate the metabolic status of COVID-19 patients, to unravel underlying pathogenic mechanism and to identify valuable biomarkers and therapeutic approaches for COVID-19.5

Based on infected cells, tissues, and body fluids from patients and by comparison with healthy individuals, multiple metabolic signatures and potential metabolite-biomarkers of COVID-19 patients were discovered.5,6 To great extent, the observed metabolite changes indicative of significant metabolic dysregulation are correlated with dysregulation of the immune function, coagulation and complement system.7–9 The most notable and distinctive metabolic reprogramming was seen for amino acids, for example, arginine and tryptophan were altered as a result of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in different studies, all closely linked to immunodysfunction and vasculopathy process of COVID-19.10–12 Such studies had been scarcely performed in Africa.

Africa as the world’s most underdeveloped regions, to identify COVID-19 might be challenging owing to its limited resources to establish surveillance and diagnosis systems, particularly in countries with low socioeconomic background. Until recently, only rare evidence about the clinical impact of COVID-19 comes from Africa, and most of them are reported from South Africa, where more than 3,818,125 cases, more than 100,471 deaths, with a case fatality rate of 2.63% have been reported by May 9, 2022 (https://covid19.who.int/). Since 2014, our team had participated in the urgent medical aid for Ebola disease in Sierra Leone, and with the onset of the COVID-19 pandemic, we were able to test and treat SARS-CoV-2 infection in the 34th Military Hospital of Republic of Sierra Leone Armed Forces hospital, which was designated as one of the medical facilities to treat COVID-19. Here, to determine the metabolomic change of COVID-19 patients from population in Africa, we performed quasi-targeted and targeted metabolomic analysis on severe and matched nonsevere patients. The aberrant glutamine and glutamate metabolism was determined as one of the most significant metabolic phenotypes in severe COVID-19 patients. To confirm the diagnosis and prognosis value of the glutamine and glutamate for COVID-19 in wider population, we performed a meta-analysis to assess the association between glutamate, glutamine, and the risk of severe COVID-19.

2 | METHODS

2.1 | Study design, participants, and data collection

This observational study was performed in Infectious Disease Prevention and Control Center in the 34th Military Hospital of Republic of Sierra Leone Armed Forces. The COVID-19 patients diagnosed according to positive SARS-CoV-2 RNA based on the WHO interim guidance (https://www.who.int/publications-detail/) were recruited from April to November, 2020. The clinical information was collected and routine laboratory tests was conducted from these patients during whole disease course. Severe COVID-19 patients referred to cases that fulfilled any of the following criteria: (1) dyspnea, respiratory rate ≥ 30/min; (2) blood oxygen saturation ≤ 93% and ratio of partial pressure of arterial oxygen to fraction of inspired oxygen < 300; and (3) lung infiltrates >50% within 24–48 h. A confirmed case with mild symptoms without presenting any of the criteria was defined as nonsevere case. Information was collected from individual patient including demographic characteristics (age, gender, ethnic, and medical conditions), clinical information, and all laboratory test results during hospitalization. All information in electric medical records were entered into an EpiData database (EpiData Association) by trained staff. All procedures were performed in accordance with the ethical standards of the institutional review board of the Sierra Leone Ethics and Scientific Review Committee and the Declaration of Helsinki. Informed consent was obtained from all participants and/or their guardians.

2.2 | Liquid chromatography-tandem mass spectrometry (LC-MS) measurement

Within 24 h after hospital admission, the whole blood samples were collected into pro-coagulation tube, centrifuged (2000g for 15 min) within 30 min, with the serum separated and prepared for LC-MS assay. Briefly, the serum was treated by acetonitrile at room temperature and then centrifuged at 14000 rpm for 10 min at 4°C. The supernatants were pipetted out and stored at 4°C before detection. From each patient, 10 μl of serum samples were pooled and used as the quality control (QC) samples, which was pretreated in parallel with the testing samples.
2.3 | LC-MS analysis

The metabolomic analysis of testing and QC samples was performed as previously described. Briefly, high-performance liquid chromatography separation was performed by using an Ultimate 3000 LC system (Thermo Scientific) coupled with an Acquity UPLC HSS T3 column (2.1 × 100 mm, 1.8 μm; Waters Corporation). The mass spectrometry was performed in both the positive and negative electrospray ionization modes (ESI+ and ESI−) using an Orbitrap Elite mass spectrometer (Thermo Scientific Waltham). The QC samples were tested at regular intervals (every 10 samples) during the whole analysis process.

Targeted metabolite profiling of glutamine related metabolites including organic acids and polyamines in serum samples was performed as previously described. Solvent mixtures containing acetonitrile and water were used to extract organic acids. For polyamine extraction, solution containing methanol, water, and formic acid was used to treat serum samples. These metabolite extracts were analyzed using LC-MS according to the procedure described above with internal standards of each concerned metabolites.

2.4 | Metabolomic data analysis and pathway enrichment analysis

All metabolic analysis were conducted using MetaboAnalyst 5.0 online tool (https://www.metaboanalyst.ca/). First, the data were log transformed and auto-scaled (Supporting Information: Figure 1), then multidimensional statistical analyses was performed by applying orthogonal partial least square discriminant analysis (OPLS-DA). The influence intensity of metabolites was measured by the variable importance in the projection (VIP) obtained from the OPLS-DA model, and metabolites with a VIP value > 1.5 were selected as potential differential metabolites. Hierarchical clustering of all potential metabolites was performed after unit variance scaling for each metabolite. Pathway enrichment analysis were based on the Kyoto Encyclopedia of Genes and Genomes database and the human metabolome database.

2.5 | Statistics

Continuous variables were described with means and standard deviations (SD) or with medians and interquartile range. Categorical variables were described with frequencies and proportions. Student's t-tests were adopted to compare the mean levels between two groups if the variable was normally distributed, otherwise, the Mann-Whitney U test were adopted. χ² tests or Fisher exact test were adopted to compare the percentages of categorical variables between groups. Wilcoxon signed-rank test was used to compare the relative content of metabolites between paired samples. Spearman rank correlation analysis was applied to assess the correlation between metabolites and clinical parameters. Statistical analysis was performed using R version 3.6.3 (R Foundation for Statistical Computing). A two-sided p < 0.05 was considered statistically significant.

2.6 | Mini meta-analysis of glutamate and glutamine in relate to COVID-19

A literature search was performed from the PubMed, and Web of Science up to Dec 2021, by using the following search terms: (multimics or metabolomics or metabolism) and (COVID-19 or SARS-Cov-2). The references of the included studies were further reviewed to identify additional studies. Studies were included in this meta-analysis if they met the following criteria: (1) case control study design with study subjects grouped as COVID-19 (+)/COVID-19 (−) or severe COVID-19/nonsevere COVID-19; (2) the metabolomic data were acquired from blood samples; (3) the raw data were provided; (4) metabolic data include the level glutamate or glutamine. Two investigators (X. L. and X. Z.) reviewed the studies independently, and for any inconsistency, a consensus was achieved by consulting a senior reviewer (W. L.).

To address the concern of incomparable spectral peaks across different studies due to various chromatographic and/or MS conditions, ROC analysis was performed for each study to calculate the optimal critical values of glutamate and glutamine for COVID-19 (+)/COVID-19 (−) or severe/non-severe. For each study, the patient was assigned into high or low group according to the cut-off value of the glutamate and glutamine, and the association with disease (COVID-19 vs. non-COVID-19) and disease outcome (severe vs. nonsevere) were calculated by using OR and 95% CI. From each study, the following data were extracted by the three investigators (X. L., W. X. and J. C.): (1) the first author; (2) study year; (3) study site; (4) sample type; (5) test method; (6) sample size; (7) metabolite results; (8) OR with 95% CI. We weighted the study-specific log ORs by inverse variance, to calculate pooled ORs with corresponding 95% CI of the association between glutamate and glutamine and the risk of disease or severe disease of COVID-19. The I² was used to assess heterogeneity (I² values of 0, 25, 50, and 75%) represented no, low, moderate, and high heterogeneity, respectively. The fixed-effect model was used as the pooling method if moderate or lower heterogeneity (I² ≤ 50%) was found; otherwise (I² > 50%), the random-effect model was adopted. All statistical analyses were performed with STATA version 15.0 (Stata Corporation). A 2-tailed p ≤ 0.05 was considered statistically significant.

3 | RESULTS

3.1 | Study design and patient

From April 2, 2020 to July 26, 2020, altogether 143 patients diagnosed with COVID-19 was enrolled in the study, 30 cases with admission delay over 15 days and 22 cases without adequate clinical information were excluded (Figure 1A). The
FIGURE 1  (See caption on next page)
quasi-targeted metabolomics method was firstly used to analyze the serum samples collected from 56 COVID-19 confirmed cases (28 patients with severe COVID-19 vs. 28 age and gender matched patients with nonsevere COVID-19). Of the 56 patients, 89.30% were male, the mean age was 53.14 (SD, 13.45), with a mean interval of 7.30 (SD 3.67) days from disease onset to test performed, which were balanced between the severe and nonsevere patients (Table 1). Significant differences in white blood cell (WBC), monocyte and neutrophil count, C-reactive protein (CRP), albumin, total and direct bilirubin (TBIL and DBIL), and so forth, were identified between severe and nonsevere COVID-19 patients.

3.2 Dysregulated glutamine/glutamate metabolism in severe COVID-19 patients

Altogether 596 metabolites were able to be identified (out of 2200+ metabolites) by alignment to the self-built database in the quasi-targeted metabolomics analysis. By OPLS-DA, the metabolomics profiles could clearly distinguish severe from nonsevere COVID-19 patients at acute infection stage (Figure 1B). Fifty-eight intergroup differential metabolites (VIP > 1.5) were determined (Supporting Information: Table 1), based on which distinct metabolic features among groups were demonstrated by hierarchical clustering (Figure 1C). Further pathway enrichment analysis suggested glutamine and glutamate metabolism to be the prominent dysregulated metabolic pathways in severe COVID-19 patients (Figure 1D). Specifically, a significant lower level of glutamine and higher level of glutamate, which corresponded with a significant reduction in the glutamine/glutamate ratio, were observed among severe COVID-19 patients (Figure 1E), implicating the downregulated glutamine bioavailability and enhanced glutaminolysis effect as relate to the severe COVID-19.

Glutamate could be converted into α-ketoglutarate (α-KG), and α-KG participated in tricarboxylic acid (TCA) cycle. Although glutamate was significantly elevated in severe patients, α-KG were comparable between severe and nonsevere COVID-19 patients. Succinate as an indirect product of glutamate, was otherwise decreased in severe patients compared to that of nonsevere patients (Figure 2). The ammonia transfer between glutamine and glutamate was also involved in conversion between aspartate and asparagine. In congruence with altered glutamate and glutamine, we found elevated asparagine and loss of aspartate in severe COVID-19 patients as well (Figure 2).

3.3 The glutamine/glutamate metabolism in relate to clinical parameters

To confirm the changes of glutamine/glutamate and related metabolites, we performed an absolute quantification by targeted metabolomics analysis. Altogether 28 glutamine/glutamate associated metabolites were evaluated on 19 pairs of matched severe and nonsevere COVID-19 patients, the detailed results was shown in Supporting Information: Table 2. (Demography and clinical data presented in Supporting Information: Table 3).

The glutamine/glutamate ratio was related to clinical parameters of routine test that were evaluated from the sample collected at the same point as that for the metabolomic analysis. A significant negative association was observed between glutamine/glutamate ratio and the level of DBIL ($r_s = -0.623, p = 0.001$), CRP($r_s = -0.603, p = 0.001$), WBC count ($r_s = -0.489, p = 0.003$), neutrophil count ($r_s = -0.473, p = 0.005$), LDH ($r_s = -0.576, p = 0.008$), ALT ($r_s = -0.432, p = 0.009$), TB ($r_s = -0.382, p = 0.022$), BUN ($r_s = -0.344, p = 0.040$), dimer ($r_s = -0.386, p = 0.042$), and a positive correlation with SPO2($r_s=0.442, p=0.005$) (Figure 3A), reflecting the glutaminolysis effect may be correlated with immune responses, organ dysfunction, and coagulation dysregulation of COVID-19 and being an indicator of systematic function of COVID-19 patients. In addition to glutamine/glutamate, there were 6 metabolites that were differentially expressed between severe and nonsevere COVID-19 patients, with the most prominent difference observed for L-Citrulline, Serotonin, and Polyamines (Figure 3B).

3.4 Mini meta-analysis on glutamine/glutamate metabolism of COVID-19

The search strategy identified 357 literatures from PubMed, and 153 from Web of Science. After excluding 306 irrelevant articles by reading titles and/or abstract and 37 literatures by reading the full text, 18 articles that involved 3177 participants were included in the meta-analysis. The detailed characteristics of the included studies are shown in Supporting Information: Table 4. Seven of them were conducted in North America (NA), four in Asia, six in Europe, and one in Oceania. Three types of samples were involved, with eight using plasma sample, nine using serum and one using red blood cells. Eight studies were performed based on Ultrahigh-Pressure Liquid Chromatography–Mass Spectrometry metabolomics, five on LC-MS, five on other methods, such as Nuclear Magnetic Resonance, Gas Chromatography–Mass Spectrometry.
|                      | Overall (N = 56) | Nonsevere (N = 28) | Severe (N = 28) | p       |
|----------------------|------------------|--------------------|----------------|---------|
| **Baseline characteristics of COVID-19 patients** |                  |                    |                |         |
| Sex, n (%)           |                  |                    |                | 1.000   |
| Male                 | 50 (89.30)       | 25 (89.30)         | 25 (89.30)     |         |
| Female               | 6 (10.70)        | 3 (10.70)          | 3 (10.70)      |         |
| Age, mean (SD), years| 53.14 (13.45)    | 53.11 (13.57)      | 53.18 (13.58)  | 0.984   |
| Interval from onset to testing, mean (SD), days | 7.30 (3.67) | 7.25 (3.41) | 7.36 (3.98) | 0.914 |

**Laboratory parameters**

|                      | Overall (N = 56) | Nonsevere (N = 28) | Severe (N = 28) | p       |
|----------------------|------------------|--------------------|----------------|---------|
| WBC, median [IQR], 10^9/L | 8.50 [5.27, 12.17] | 5.40 [4.55, 7.75] | 11.90 [9.50, 14.60] | <0.001 |
| Lymphocyte, median [IQR], 10^9/L | 1.70 [1.28, 2.40] | 2.20 [1.40, 2.50] | 1.60 [1.20, 1.90] | 0.115 |
| Monocyte, median [IQR], 10^9/L | 0.40 [0.30, 0.70] | 0.30 [0.30, 0.50] | 0.60 [0.40, 0.90] | 0.001 |
| Neutrophils, median [IQR], 10^9/L | 5.75 [2.98, 9.62] | 3.40 [2.40, 4.90] | 9.60 [7.40, 11.80] | <0.001 |
| HGB, median [IQR], g/L | 145.50 [127.75, 157.00] | 145.00 [129.00, 151.50] | 146.00 [122.00, 166.00] | 0.458 |
| PLT, median [IQR], 10^9/L | 162.50 [126.00, 225.25] | 152.00 [110.00, 212.50] | 191.00 [130.00, 226.00] | 0.170 |
| ALB, median [IQR], g/L | 40.10 [36.25, 46.50] | 45.20 [38.08, 49.00] | 37.90 [34.75, 41.15] | 0.002 |
| TP, median [IQR], g/L | 73.20 [67.45, 76.90] | 72.55 [67.53, 75.82] | 74.40 [67.95, 78.15] | 0.596 |
| ALT, median [IQR], U/L | 38.00 [23.55, 59.80] | 32.85 [22.18, 49.95] | 46.20 [26.90, 73.00] | 0.170 |
| AST, median [IQR], U/L | 29.60 [25.90, 37.10] | 29.80 [26.30, 33.80] | 29.30 [25.77, 45.75] | 0.310 |
| TBIL, median [IQR], umol/L | 13.70 [11.85, 20.30] | 12.55 [10.80, 16.30] | 14.30 [12.90, 21.85] | 0.040 |
| DBIL, median [IQR], umol/L | 6.50 [5.20, 8.35] | 5.65 [4.77, 6.55] | 6.90 [6.25, 8.95] | 0.009 |
| GLU, median [IQR], mmol/L | 7.25 [6.10, 8.70] | 6.10 [5.80, 6.90] | 8.10 [7.50, 11.25] | <0.001 |
| BUN, median [IQR], mmol/L | 6.30 [4.30, 11.00] | 4.40 [3.20, 6.30] | 7.85 [4.80, 11.17] | 0.006 |
| CREA, median [IQR], umol/L | 102.00 [86.00, 148.50] | 99.00 [86.00, 121.00] | 103.00 [90.50, 151.50] | 0.583 |
| UA, median [IQR], umol/L | 393.95 [295.28, 462.60] | 364.45 [295.28, 409.40] | 424.05 [308.25, 502.93] | 0.275 |
| LDH, median [IQR], U/L | 279.95 [196.43, 400.02] | 209.90 [178.55, 312.50] | 353.80 [261.88, 505.15] | 0.025 |
| CRP, median [IQR], mg/L | 70.76 [20.45, 114.47] | 20.45 [4.44, 65.68] | 103.72 [73.97, 134.10] | <0.001 |
| D-D, median [IQR], mg/L | 2.74 [0.33, 8.78] | 0.33 [0.28, 1.78] | 8.12 [4.38, 15.00] | <0.001 |
| Comorbidities, n (%) | 40 (71.40) | 16 (57.10) | 24 (85.70) | 0.038 |

**Symptoms and vital signs**

|                      | Overall (N = 56) | Nonsevere (N = 28) | Severe (N = 28) | p       |
|----------------------|------------------|--------------------|----------------|---------|
| Fever, n (%)         | 37 (66.10)       | 18 (64.30)         | 19 (67.90)     | 1.000   |
| Cough, n (%)         | 34 (60.70)       | 15 (53.60)         | 19 (67.90)     | 0.412   |
| Dyspnea, n (%)       | 24 (42.90)       | 3 (10.70)          | 21 (75.00)     | <0.001  |
| Fatigue, n (%)       | 26 (46.40)       | 12 (42.90)         | 14 (50.00)     | 0.789   |
| Temperature, mean (SD), °C | 36.58 (0.49) | 36.52 (0.35) | 36.63 (0.60) | 0.435   |
| SPO₂, mean (SD), %   | 91.64 (6.90)     | 97.00 (1.61)       | 86.29 (5.89)   | <0.001  |
| SBP, mean (SD), mmHg | 138.61 (26.08)   | 130.75 (18.46)     | 146.46 (30.28) | 0.023   |
| DBP, mean (SD), mmHg | 83.50 (15.24)    | 80.79 (12.87)      | 86.21 (17.10)  | 0.185   |
| HR, mean (SD),/min   | 95.18 (18.02)    | 85.04 (13.99)      | 105.32 (15.89) | <0.001  |
| RR, mean (SD),/min   | 24.25 (4.76)     | 20.46 (2.66)       | 28.04 (3.07)   | <0.001  |

Abbreviations: ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, urea nitrogen; CREA, creatine; CRP, C-reactive protein; DBP, diastolic blood pressure; D-D, d-dimer; DBIL, direct bilirubin; GLU, glucose; HGB, hemoglobin; HR, heart rate; IQR, interquartile range; LDH, lactate dehydrogenase; PLT, platelet; RR, respiratory rate; SBP, systolic blood pressure; SD, standard deviation; SPO₂, oxygen saturation; TBIL, total bilirubin; TP, total protein; UA, uric acid; WBC, white blood cell.
Studies that provided original data were used to evaluate the relationship between the COVID-19 infection and the level of glutamate or glutamine (in 16 studies), between the disease severity and the level of glutamate (in six studies) or glutamine (in eight studies). The pooled odd ratio of glutamate for the risk of COVID-19 infection was determined to be 2.02 (95% CI: 1.17–3.50; $I^2 = 86.1\%$) (Figure 4A), and for the risk of severe COVID-19 was 2.28 (95% CI: 1.14–4.56; $I^2 = 65.5\%$) (Figure 4C). These results indicated that elevated glutamate was related to an increased risk of COVID-19 infection and severe COVID-19. In contrast, the elevated level of glutamine was related to a decreased risk of infection and severe COVID-19, with the pooled OR of glutamine for the risk of COVID-19 infection and severe COVID-19 estimated as 0.30 (95% CI: 0.20–0.44; $I^2 = 68.0\%$) (Figure 4B), and 0.44 (95% CI: 0.19–0.98; $I^2 = 80.2\%$) (Figure 4D), respectively.

## DISCUSSION

Several previous studies based on the metabolome profiling have emphasized the impairment of amino acid metabolism in COVID-19.\textsuperscript{6} Our metabolome results further showed significantly decreased glutamine and elevated glutamate of severe COVID-19 patients compared to nonsevere patients. The core metabolites of this metabolism, glutamine, and glutamate were correlated with hematological, inflammatory, and organ dysfunction of the patients, corroborating the important role of glutamine and glutamate metabolism during the clinical process. Via meta-analysis of previously published metabolomic results of COVID-19 patients, we further verified the finding that glutamine and glutamate metabolism was significantly altered in COVID-19 patients, especially in severe patients.

Glutamine is a nonessential amino acid involved in multiple physiological metabolic function, such as energy generation via TCA cycle, lipid and purine synthesis, and glutathione production.\textsuperscript{17} Glutaminase converts glutamine to glutamate, with the latter generating $\alpha$-KG to enter the TCA cycle for adenosine triphosphate production. Glutamine/glutamate metabolism was also involved in production of other macromolecules. The ammonia transfer from glutamine to glutamate is also involved in the balance of asparagine and aspartate.\textsuperscript{18} And aspartate was the precursor of purine and pyrimidine\textsuperscript{19} that could be used to synthesize viral RNA and DNA. Furthermore, glutamine/glutamate enables the formation of citrulline and other intermediate compounds in urea cycle, and glutamine/glutamate are also precursors of glutathione, an antioxidant compound that plays an important role in preventing oxidative stress in severe infection.\textsuperscript{20} Taken together, glutamine metabolism provides metabolic intermediates that are required for viral proliferation, including energy supply, anaplerosis, virus assembly, cell growth, and cell survival,\textsuperscript{21} therefore is highly likely manipulated to support the

---

**Figure 2** Disturbed metabolisms associated with glutamine/glutamate metabolism in severe COVID-19 patients. Red represents the upregulated metabolites in severe COVID-19, green represents the downregulated metabolites in severe COVID-19, blue represents the unchanged metabolites, and gray represents the undetected metabolites. COVID-19, coronavirus disease 2019.
viral replication. Actually, the altered glutamine utilization and metabolism had been previously reported in multiple virus infection. In cells infected by herpes simplex virus (HSV)-1, vaccinia virus (VACV), the glutamine-dependent anaplerotic pathway is activated to sustain energy production and nucleotide synthesis for viral replication.\textsuperscript{22,23} Deprivation of glutamine leads to impairments of VACV replication.\textsuperscript{24} Inhibition of glutamine metabolism reduced or inhibited viral replication such as coxsackie B3 virus,\textsuperscript{25} hepatitis C virus.\textsuperscript{26}

|        | $r_s$ | $P$  |
|--------|-------|------|
| DBIL   | -0.623| 0.001|
| CRP    | -0.603| 0.001|
| WBC    | -0.489| 0.003|
| SPO$_2$| 0.442 | 0.005|
| NEUT   | -0.473| 0.005|
| LDH    | -0.576| 0.008|
| ALT    | -0.432| 0.009|
| TB     | -0.382| 0.022|
| BUN    | -0.344| 0.040|
| D-D    | -0.386| 0.042|
| MONO   | -0.340| 0.049|

\textbf{FIGURE 3} Targeted metabolomics analysis of patients with COVID-19. (A) Correlation between glutamine/glutamate ratio and laboratory parameters and vital signs. Correlation coefficient was calculated by spearman rank correlation analysis. (B) Additional differential metabolites between severe and nonsevere COVID-19 patients. COVID-19, coronavirus disease 2019.
COVID-19 patients, especially severe COVID-19 patients, showed both reduced level of glutamine and elevated level of glutamate which indicated increased utilization of glutamine. However, the detailed association between glutamine and glutamate level with disease severity remained undetermined, and other related metabolites was not examined simultaneously. Our finding was also in line with previous studies on metabolic analysis, where metabolites in glutamine/glutamate related metabolic pathways were likewise significantly altered, featured by elevated asparagine, reduced aspartate, succinate and citrulline among severe COVID-19 patients compared with nonsevere patients.

Before the current study, numerous indicators that highlighted hematological abnormalities (e.g., reduced Lymphocytes and their subsets), tissue damage (e.g., abnormally altered LDH, AST, ALT, and other biochemical parameters), coagulation dysregulation (e.g., increased d-dimers and fibrinogen levels), clinical inflammatory overexpression (increased CRP, procalcitonin, and ferritin) and immunological and transcriptomic signatures (proinflammatory cytokines such as IL-1 alpha, IL-6, and IL-8) had been implicated for their usage as biomarkers of disease severity of COVID-19. Based on high-throughput RNA sequencing technology, many genetic signatures were identified to be associated with COVID-19 disease progression, with most of them involved in interferon responses, cell death, inflammation, and regulation of immune cell function. Glutamine metabolism on the other hand, was supposed to participates in vast majority of above-mentioned pathways, process of immune regulation or cellular functions. For example, the

FIGURE 4 Forest plot of the odds ratio (ORs) with 95% confidence intervals (CIs) of the association between glutamate (A), glutamine (B) and the risk of infection; the association between glutamate (C), glutamine (D) and severity of COVID-19. COVID-19, coronavirus disease 2019.
glutamine metabolism is required for B cell proliferation, germinal center formation and memory B cell generation.\textsuperscript{31} Glutamine regulates T cell proliferation and affects the differentiation of naïve CD4\(^+\) T cells to Th1 cells,\textsuperscript{32} and it's also crucial for the fate decision of Th17/Treg.\textsuperscript{33} α-KG, a production of glutaminolysis, is reported to promote alternative activation of macrophage and ameliorates inflammation.\textsuperscript{34} Glutamine promotes neutrophil phagocytosis and bacterial killing activities.\textsuperscript{35,36} The clinical application of glutamine in HIV infected patients, increased the number of CD4\(^+\) T cells and decreased the serum levels of CRP, interferon-inducible gamma protein-10, regulated on activation normal T cell expressed and secreted, and macrophage inflammatory protein-1b.\textsuperscript{19} Furthermore, a clinical trial showed that oral glutamine supplementation shortened the length of hospital stay and reduced the need for intensive care in patients with COVID-19.\textsuperscript{37} In addition, some investigators proposed that inhibitors of glutamine metabolism, like Azaserine and δ-diazo-5-oxo-L-norleucine, instead of glutamine supplementation seems to be a better strategy to reduce or abolish viral replication.\textsuperscript{19} But whether glutamine supplementation or inhibitors of glutamine metabolism could restore immune function of COVID-19 patients or show a direct anti-SARS-COV-2 effect requires further investigation.

Long COVID-19 is emphasized by researchers. Recent surveys showed that it influenced approximately 14% adults\textsuperscript{38} and approximately 21% children and adolescents.\textsuperscript{39} The frequently reported symptoms of long COVID-19 include headache, anosmia, dyspnea, and diarrhea.\textsuperscript{40} The underlying biological mechanism remains to be explored. Hyperinflammation, oxidative stress, and endothelial cell injury have been suggested as the drivers of long COVID-19.\textsuperscript{41,42} As a pluripotent biological process, glutamine/glutamate metabolism is involved in immune regulation\textsuperscript{43} and oxidative stress.\textsuperscript{44} Supplementation of glutamine analogue also attenuates endothelial cell injury.\textsuperscript{45} In COVID-19 patients, administration of glutamine decreased levels of inflammatory cytokines and oxidative stress indicator, and increased total antioxidant capacity.\textsuperscript{46} The role of glutamine/glutamate metabolism in pathogenesis of long COVID-19 remains to be investigated and it is a promising therapeutic target to alleviate symptoms of long COVID-19.

Our data shed light on the molecular changes reflected in COVID-19 sera, which could potentially yield critical diagnostic markers or therapeutic targets for managing severe COVID-19 patients. The application of the glutamine metabolites as powerful markers or therapeutic targets for managing severe COVID-19 and alleviate symptoms of long COVID remains to be investigated and it is a promising therapeutic target to respiratory samples post SARS-CoV-2 infection.\textsuperscript{49–51}

Despite these limitations, the current study for the first time identified glutamine and glutamate metabolism to be associated with COVID-19 severity in African populations, with the findings corroborated by accumulating data from studies performed in other ethnics than the African. Our data shed light on the ubiquitous change of glutamine and glutamate metabolite in COVID-19 sera, which could potentially yield critical diagnostic markers or therapeutic targets for managing severe COVID-19 patients.

**AUTHOR CONTRIBUTIONS**

Xiao-kun Li, Bo Tu, Xiao-Ai Zhang, Wen Xu, Peng-fei Hao, Reginald Cole, Mohamed Boie Jalloh, Wei Liu, and Wei-wei Chen participated in the study design and data collection. Biao Xu, Jun-Jie Zheng, Jia-hao Chen, Qing-bin Lu, Chang Li and Stephen Sevalie analyzed the data and wrote the manuscript. Xiao-kun Li, Stephen Sevalie, Wei Liu and Wei-wei Chen critically reviewed the manuscript. All participated authors critically reviewed the manuscript.

**ACKNOWLEDGMENTS**

The authors would like to thank all patients who contributed data and clinicians in the 34th Military Hospital of Republic of Sierra Leone Armed Forces. This study was supported by National Key R&D Program of China (2021YFC2301801), Natural Science Foundation of China (No. 81825019) and Biomedical research foundation (19SWAQ13). The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**CONFLICT OF INTEREST**

The authors declare no conflict of interest.

**DATA AVAILABILITY STATEMENT**

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Data available on request from the authors

**ORCID**

Wei Liu https://orcid.org/0000-0002-9302-8170  
Wei-Wei Chen https://orcid.org/0000-0001-6026-7813

**REFERENCES**

1. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109: 102433. doi:10.1016/j.jaut.2020.102433
2. Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M. The cytokine storm in COVID-19: an overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev. 2020;53:25-32. doi:10.1016/j.cytogfr.2020.05.003

3. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. JAMA. 2020;323(20):2052-2059. doi:10.1001/jama.2020.6775

4. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323(13):1239-1242. doi:10.1001/jama.2020.2648

5. Shen T, Wang T. Metabolic reprogramming in COVID-19. Int J Mol Sci. 2021;22(11):4147. doi:10.3390/ijms22111475

6. Costanzo M, Caterino M, Fedele R, et al. COVIDomics: the proteomic and metabolomic signatures of COVID-19. Int J Mol Sci. 2022;23(5):2414. doi:10.3390/ijms23052414

7. Bruzzone C, Bizkarguenaga M, Gil-Redondo R, et al. SARS-CoV-2 infection dysregulates the metabolic and lipidomic profiles of serum. Sci. 2020;23(10):101645. doi:10.1016/j.scis.2020.101645

8. Shen B, Yi X, Sun Y, et al. Proteomic and metabolic characterization of COVID-19 patient sera. Cell. 2020;182(1):59-72.e15. doi:10.1016/j.cell.2020.05.032

9. Wu D, Shu T, Yang X, et al. Plasma metabolic and lipidomic alterations associated with COVID-19. Natl Sci Rev. 2020;7(7):1157-1168. doi:10.1093/nsr/nwa086

10. Durante W. Targeting arginine in COVID—pathogenesis, immunopathology and vascopathology. Metabolites. 2022;12(3):240. doi:10.3390/metabo12030240

11. Attila A, Alay H, Yaman ME, et al. The serum amino acid profile in COVID-19. Amino Acids. 2021;53(10):1569-1588. doi:10.1007/s00726-021-03081-w

12. Rees CA, Rostad CA, Mantus G, et al. Altered amino acid profile in patients with SARS-CoV-2 infection. Proc Natl Acad Sci U S A. 2021;118(25). doi:10.1073/pnas.2101708118

13. Liu A, Zhou W, Qu L, et al. Altered urinary amino acids in children with autism spectrum disorders. Front Cell Neurosci. 2019;13:7. doi:10.3389/fncel.2019.00007

14. Yu C, Liu R, Xie C, et al. Quantification of free polyamines and their metabolites in biofluids and liver tissue by UHPLC-MS/MS: application to identify the potential biomarkers of hepatocellular carcinoma. Anal Bioanal Chem. 2015;407(22):6891-6897. doi:10.1007/s00216-015-8860-6

15. Li B, Li L, Li M, et al. Microbiota depletion impairs thermogenesis of brown adipose tissue and browning of White adipose tissue. Cell Rep. 2019;26(10):2720-2727.e2725. doi:10.1016/j.celrep.2019.02.015

16. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical research ed). 2003;327(7414):557-560. doi:10.1136/bmj.327.7414.557

17. Curi R, Lagranha CJ, Doi SQ, et al. Molecular mechanisms of glutamine action. J Cell Physiol. 2005;204(2):392-401. doi:10.1002/jcp.20339

18. Balasubramanian MN, Butterworth EA, Kilberg MS. Asparagine synthetase: regulation by cell stress and involvement in tumor biology. Am J Physiol: Endocrinol Metab. 2013;304(8):E789-E799. doi:10.1152/ajpendo.00115.2013

19. Hirabara SM, Gorja R, Levada-Pires AC, et al. Host cell glutamine metabolism as a potential antiviral target. Clin Sci. 2021;135(2):305-325. doi:10.1042/CS20201042

20. Millaraki M, Briassoulis P, Ilia S, et al. Oxidant/Antioxidant status is impaired in sepsis and is related to anti-apoptotic, inflammatory, and innate immunity alterations. Antioxidants (Basel, Switzerland). 2022;11(2):231. doi:10.3390/antiox11020231

21. Zhu Y, Li T, Ramos da Silva S, et al. A critical role of glutamine and asparagine γ-nitrogen in nucleotide biosynthesis in cancer cells hijacked by an oncogenic virus. mBio. 2017;8(4):e01179-17. doi:10.1128/mBio.01179-17

22. Vastag L, Koyuncu E, Grady SL, Shenk TE, Rabinowitz JD. Divergent effects of human cytomegalovirus and herpes simplex virus-1 on cellular metabolism. PLoS Pathog. 2011;7(7):e1002124. doi:10.1371/journal.ppat.1002124

23. Mazzon M, Castro C, Roberts LD, Griffin JL, Smith GL. A role for vaccinia virus protein C16 in reprogramming cellular energy metabolism. J Gen Virol. 2015;96(Pt 2):395-407. doi:10.1099/vir.0.069591-0

24. Fontaine KA, Camarda R, Lagunoff M. Vaccinia virus requires glutamine but not glucose for efficient replication. J Virol. 2014;88(8):4366-4374. doi:10.1128/JVI.03134-13

25. Abd El-Baky HH, El-Baroty GS. Spirulina maxima l-asparaginase: immobilization, antiviral and antiproliferation activities. Recent Pat Biotechnol. 2020;14(2):154-163. doi:10.2174/187220831366619114151344

26. Lévy PL, Duponchel S, Eischied H, et al. Hepatitis C virus infection triggers a tumor-like glutamine metabolism. Hepatology (Baltimore, Md). 2017;65(3):789-803. doi:10.1002/hep.28949

27. Thomas T, Stefanoni D, Reisz JA, et al. COVID-19 infection alters kynurenine and fatty acid metabolism, correlating with IL-6 levels and renal status. JCI Insight. 2020;5(14):e140327. doi:10.1172/jci.insight.140327

28. Li T, Ning N, Li B, et al. Longitudinal metabolomics reveals ornithine cycle dysregulation correlates with inflammation and coagulation in COVID-19 severe patients. Front Microbiol. 2021;12:723818. doi:10.3389/fmicb.2021.723818

29. Papadopoulou G, Manoloudi E, Repousi N, Skoura L, Hurst T, Pires AC, et al. Host cell glutamine metabolism as a potential antiviral target. Clin Sci (Lond). 2021;135(2):197-205. doi:10.1042/CS20201042

30. Nakaya M, Xiao Y, Zhou H, et al. Inflammatory T cell responses rely on amino acid transporter ASCT2 facilitation of glutamine uptake and mTORC1 kinase activation. Immunity. 2014;40(5):692-705. doi:10.1016/j.immuni.2014.04.007

31. Yang G, Xia Y, Ren W. Glutamine metabolism in Th17/Treg cell fate: applications in Th17 cell-associated diseases. Sci China Life Sci. 2021;64(2):221-233. doi:10.1007/s11427-020-1703-2

32. Liu PS, Wang H, Li X, et al. α-ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming. Nature Immunol. 2018;19(9):985-994. doi:10.1038/ni.3796

33. Ogle CK, Ogle JD, Mao JX, et al. Effect of glutamine on phagocytosis and bacterial killing by normal and pediatric burn patient neutrophils. JPEN J Parenter Enteral Nutr. 1994;18(2):128-133. doi:10.1177/014860719418020128

34. Furukawa S, Saito H, Fukatsu K, et al. Glutamine-enhanced bacterial killing by neutrophils from postoperative patients. Nutrition (Burbank, Los Angeles County, Calif). 1997;13(10):863-869. doi:10.1016/s0899-9007(97)00271-2

35. Cengiz M, Borku Uysal B, Ilkimir H, et al. Effect of oral L-glutamine supplementation on Covid-19 treatment. Clin Nutr Exp. 2020;33:24-31. doi:10.1016/j.jclinex.2020.07.003
38. Daugherty SE, Guo Y, Heath K, et al. Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ (Clinical research ed). 2021;373:n1098. doi:10.1136/bmj.n1098

39. Buonsenso D, Di Gennaro L, De Rose C, et al. Long-term outcomes of pediatric infections: from traditional infectious diseases to long covid. Future Microbiol. 2022;17:551-571. doi:10.2217/fmb-2022-0031

40. Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. A clinical case definition of post-COVID-19 condition by a delphi consensus. Lancet Infect Dis. 2022;22(4):e102-e107. doi:10.1016/s1473-3099(21)00703-9

41. Vollbracht C, Kraft K. Oxidative stress and Hyper-Inflammation as major drivers of severe COVID-19 and long COVID: implications for the benefit of High-Dose intravenous vitamin C. Front Pharmacol. 2022;13:899198. doi:10.3389/fphar.2022.899198

42. Ahamed J, Laurence J. Long COVID endotheliopathy: hypothesized mechanisms and potential therapeutic approaches. J Clin Invest. 2022;132(15):e161167. doi:10.1172/jci161167

43. Cruzat V, Macedo Rogero M, Noel Keane K, Curi R, Newsholme P. Glutamine: metabolism and immune function, supplementation and clinical translation. Nutrients. 2018;10(11):1564-1594. doi:10.3390/nu10111564

44. Di Renzo L, De Lorenzo A, Fontanari M, et al. Immunonutrients involved in the regulation of the inflammatory and oxidative processes: implication for gamete competence. J Assist Reprod Genet. 2022;39(4):817-846. doi:10.1007/s10815-022-02472-6

45. Herzog R, Bartosova M, Tarantino S, et al. Peritoneal dialysis fluid supplementation with alanyl-glutamine attenuates conventional dialysis fluid-mediated endothelial cell injury by restoring perturbed cytoprotective responses. Biomolecules. 2020;10(12):1678. doi:10.3390/biom10121678

46. Mohajeri M, Horriaklhah E, Mohajery R. The effect of glutamine supplementation on serum levels of some inflammatory factors, oxidative stress, and appetite in COVID-19 patients: a case-control study. Inflammopharmacology. 2021;29(6):1769-1776. doi:10.1007/s10787-021-00881-0

47. Wang C, Kang K, Lan X, et al. Cytokine levels in sputum, not serum, May be more helpful for indicating the damage in the lung and the prognosis of severe COVID-19—a case series. J Infect. 2021;83(5):e6-e9. doi:10.1016/j.jinf.2021.08.026

48. Merenstein C, Liang G, Whiteside SA, et al. Signatures of COVID-19 severity and immune response in the respiratory tract microbiome. mBio. 2021;12(4):e0177721. doi:10.1128/mBio.01777-21

49. Xiong Y, Liu Y, Cao L, et al. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerg Microbes Infect. 2020;9(1):761-770. doi:10.1080/22221751.2020.1747363

50. Saris A, Reijnders TDY, Nossent EJ, et al. Distinct cellular immune profiles in the airways and blood of critically ill patients with COVID-19. Thorax. 2021;76(10):1010-1019. doi:10.1136/thoraxjnl-2020-216256

51. Wang C, Kang K, Gao Y, et al. Cytokine levels in the body fluids of a patient with COVID-19 and acute respiratory distress syndrome: a case report. Ann Intern Med. 2020;173(6):499-501. doi:10.7326/m20-0354

SUPPORTING INFORMATION
Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Li X-k, Tu B, Zhang X-A, et al. Dysregulation of glutamine/glutamate metabolism in COVID-19 patients: a metabolism study in African population and mini meta-analysis. J Med Virol. 2022;95:e28150. doi:10.1002/jmv.28150